American Conference Institute (ACI) is hosting its 5th Annual Summit on Life Sciences IP Due Diligence on November 15-16 at The Westin Copley Place in Boston. The conference will provide life sciences and legal professionals with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence. Program sessions will discuss what to look for during the due diligence process, when to report findings, how to communicate effectively within and across teams, and when to adjust your expectations and decisions as the process proceeds.
On November 15, Greenberg Traurig Shareholder David Dykeman, Co-Chair of the firm's global Life Sciences and Medical Technology group, will moderate the session, "Ownership and Inventorship 2.0: Common and Contemporary IP Due Diligence Landmines for the Life Sciences." This session will focus on reviewing legal developments on the question of whether AI or technology can be an inventor and the implications for life sciences companies employing AI technologies; developing unique due diligence strategies for life sciences IP assets involving AI, machine learning, proprietary data, software; analyzing who owns data, genetic data, and checking for data bias; determining inventorship and ownership with multiple inventors and assessing the risk of correlated litigation; and Analyzing the target company’s policies and relationships.